Venn Acquires Cancer Immunotherapy Antibody
By Press Release on April 23, 2018
Venn Therapeutics has completed an exclusive licensing deal with the University of California, San Francisco (UCSF) to advance its novel integrin αvβ8 antibody, created by a team of preeminent scientists at UCSF, led by Dr. Stephen Nishimura.
Read More
Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for $567 MM
December 07, 2017
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms...